Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

Summary

This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.

Timeline

Start

2026-02-16

Primary completion

2026-10

Completion

2026-12

Drugs

Indications